3094-09-5
3094-09-5
Chemical Structure
Doxifluridine
Synonym(s): Ro 21-9738; 5-Fluoro-5'-deoxyuridine; 5'-DFUR
- CAS No.: 3094-09-5
- Formula:C9H11FN2O5
- Molecular Weight:246.19
IUPAC Name: 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione
InChIKey: ZWAOHEXOSAUJHY-ZIYNGMLESA-N
SMILES: O=C(N1)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=C(F)C1=O
Biological Activity: Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Doxifluridine | 99.44% | Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxifluridine (Standard) | ≥98% | Doxifluridine (Standard) is the analytical standard of Doxifluridine. This product is intended for research and analytical applications. Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxifluridine-d3 | Doxifluridine-d3 is deuterated labeled Doxifluridine (HY-B0021). Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxifluridine-d2 | Doxifluridine-d2 is the deuterium labeled Doxifluridine. Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Naganuma Y, et al. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci. 2011 Aug;102(8):1545-52. [Content Brief]
- [2]. Berne M, et al. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest. 1988;6(4):377-83. [Content Brief]
- [3]. Di Bartolomeo M, et al. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study. Tumori. 1999 May-Jun;85(3):211-3. [Content Brief]
